Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera

Novel therapies targeting hematocrit control, including rusfertide under FDA priority review and other agents like sapablursen and divesiran, are advancing treatment for polycythemia vera by reducing the need for phlebotomies and improving patient outcomes.

This Wire brief sits within Fusion42's coverage of Biotech.